MX2023010542A - Uso de mevidaleno y otros moduladores alostéricos positivos d1 para ralentizar la progresión de la enfermedad de parkinson. - Google Patents

Uso de mevidaleno y otros moduladores alostéricos positivos d1 para ralentizar la progresión de la enfermedad de parkinson.

Info

Publication number
MX2023010542A
MX2023010542A MX2023010542A MX2023010542A MX2023010542A MX 2023010542 A MX2023010542 A MX 2023010542A MX 2023010542 A MX2023010542 A MX 2023010542A MX 2023010542 A MX2023010542 A MX 2023010542A MX 2023010542 A MX2023010542 A MX 2023010542A
Authority
MX
Mexico
Prior art keywords
mevidalen
parkinson
slowing
disease progression
positive allosteric
Prior art date
Application number
MX2023010542A
Other languages
English (en)
Inventor
Kevin Michael Biglan
Kjell Anders Ivan Svensson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2023010542A publication Critical patent/MX2023010542A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con métodos de tratamiento y regímenes de dosificación usando mevidaleno, también descrito como 2-(2,6-diclorofenil)-1-[(1S,3R)-3-(hidroximetil)-5-(3- hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1H)- il]etanona, y/o composiciones farmacéuticas de este, para ralentizar la progresión de la enfermedad de Parkinson.
MX2023010542A 2021-03-09 2022-03-08 Uso de mevidaleno y otros moduladores alostéricos positivos d1 para ralentizar la progresión de la enfermedad de parkinson. MX2023010542A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163158460P 2021-03-09 2021-03-09
PCT/US2022/019339 WO2022192255A1 (en) 2021-03-09 2022-03-08 Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression

Publications (1)

Publication Number Publication Date
MX2023010542A true MX2023010542A (es) 2023-11-24

Family

ID=80937323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010542A MX2023010542A (es) 2021-03-09 2022-03-08 Uso de mevidaleno y otros moduladores alostéricos positivos d1 para ralentizar la progresión de la enfermedad de parkinson.

Country Status (10)

Country Link
US (1) US20240165101A1 (es)
EP (1) EP4304577A1 (es)
JP (1) JP2024509272A (es)
KR (1) KR20230154968A (es)
CN (1) CN117337173A (es)
AU (1) AU2022234226A1 (es)
BR (1) BR112023018196A2 (es)
CA (1) CA3211578A1 (es)
MX (1) MX2023010542A (es)
WO (1) WO2022192255A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
SI3204359T1 (sl) 2014-10-08 2020-10-30 UCB Biopharma SRL Tetrahidroizokinolinski derivati
AR106332A1 (es) 2015-10-23 2018-01-03 Lilly Co Eli Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
JP2022514659A (ja) * 2018-12-18 2022-02-14 イーライ リリー アンド カンパニー ドーパミン作動性ｃｎｓ障害の治療におけるｌｙ３１５４２０７の使用のための用量レジメン
MA56445A (fr) * 2019-07-01 2022-05-11 UCB Biopharma SRL Dérivé de tétrahydroisoquinoléine substitué utilisé comme modulateur allostérique positif de d1
AU2020299953A1 (en) * 2019-07-01 2022-01-06 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator

Also Published As

Publication number Publication date
CA3211578A1 (en) 2022-09-15
EP4304577A1 (en) 2024-01-17
WO2022192255A1 (en) 2022-09-15
KR20230154968A (ko) 2023-11-09
AU2022234226A1 (en) 2023-09-14
CN117337173A (zh) 2024-01-02
JP2024509272A (ja) 2024-02-29
BR112023018196A2 (pt) 2023-12-12
US20240165101A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
MA47079A (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
JOP20220130A1 (ar) مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
PH12018500859A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease
MA35716B1 (fr) Formulations pharmaceutiques
EA201070012A1 (ru) МЕТАБОЛИТЫ (R)-3-(4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА, ИНГИБИТОРА JANUS КИНАЗ
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MA43313B1 (fr) Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA38425B1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
SA520420382B1 (ar) مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1
MX2023010540A (es) Uso de mevidaleno y otros moduladores alostéricos positivos d1 en el tratamiento de alucinaciones y psicosis relacionadas con la demencia.
MX2023010542A (es) Uso de mevidaleno y otros moduladores alostéricos positivos d1 para ralentizar la progresión de la enfermedad de parkinson.
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
EA201792558A1 (ru) Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль
EA201992817A1 (ru) Синергетические композиции, содержащие (r)-димирацетам (1) и (s)-димирацетам (2) в нерацемическом соотношении
ZA202200331B (en) Naltrexone formulation
MA56540A (fr) Procédés et intermédiaires pour la préparation de 2-(2,6-dichlorophényle))-1-[(1s,3r)-3-(hydroxyméthyl)-5-(3-hydroxy-3-méthylbutyl)-1-méthyl-3,4-dihydroisoquinolin-2(1)-yl]éthénone
MA52370B1 (fr) Dérivés de la pyridine et leurs utilisations thérapeutiques comme inhibiteurs du trpc6
FR3028762B1 (fr) Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine